Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.38−0.05 (-11.40%)
Close on Nov 19, 2026Market cap $220.68KP/E –Yield –
Virax Biolabs free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2026 it was -$4.88M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$4.88M | – |
| FY2025 | Mar 31, 2025 | -$5.17M | – |
| FY2024 | Mar 31, 2024 | -$7.35M | – |
See a number that looks wrong?